IMMB - Immunotech Laboratories, Inc.
Immunotech -Business OverView
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
After decades of research, we determined that it was time to take Immunotech Laboratories, Inc. (formerly International Technology Systems, Inc.) and our product to the next level. Therefore, we are glad to inform you that Immunotech Laboratories, Inc. is currently trading publicly under the ticker symbol of IMMB (Pink Sheets / OTC.NASDAQ Exchange).
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Products and Services
IMMB Flagship Product
Immune Therapeutic Vaccine-1 (ITV-1)
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction
(IPF), which studies have shown is effective in the treatment
of HIV/AIDS. IPF is the active drug substance of ITV-1 and
is a purified extract of porcine pepsin. ITV-1 has been shown
to modulate the immune system.
In Harry Zhabilov’s paper, Immune Therapeutic Vaccine (ITV): A Fusion Inhibitor and Immunomodulator, our Chief Science Officer details his motivation for exploring this therapeutic avenue,
and the promising results of extensive laboratory testing.
Irreversible Pepsin Fraction (IPF)
Irreversible Pepsin Fraction (IPF) is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.
ITV-2 will utilize Immunotech Laboratories’ IPF platform technology. This product’s testing is scheduled to begin soon. Come back soon for more information and updates on this exciting product.
ITV-3 will utilize Immunotech Laboratories’ IPF platform technology. This product’s testing is scheduled to begin soon. Come back soon for more information and updates on this exciting product.
ITV-4 HIV Vaccine
Preclinical developement for the ITV-4 HIV Vaccine is scheduled to begin in the 4th Quarter of 2012.
Immunotech Laboratories, Inc. is a publicly traded on the OTC Market under the symbol, “IMMB”, and within the OTC Pink Limited market tier. As such, Business, operational and financial information on IMMB is available to public view.
Visit http://www.otcmarkets.com/stock/IMMB/company-info to see complete details
A/S : 3 Billion
O/S : 60 Million
(Please note the share structure posted is what we have gathered but can change on a daily basis , please contact the company or transfer agent to get the most current information.)
Incorporated In: NV. Yr. 2009
Interstate Transfer Co.
6084 South 900 East
Salt Lake City, 84121
The following Press Release has not been investigated by StockGoodies, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable company you should NOT assume that a press wire hosted by a website you are familiar with is accurate, just because it is on their site. Stock Goodies will not be held responsible for any news release including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
Marketwire - (Fri, Mar 1)
Immunotech Relocates to New Research & Development Laboratory Facility
MedicinesPR Newswire - (Wed, Feb 20)
Immunotech Laboratories Inc. Announces Clinical Trials Updates For Company's AIDS-HIV "IPF"
Marketwire - (Tue, Feb 19)
Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc.
PR Newswire - (Wed, Feb 13)
Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Company's Patented "IPF" HIV-AIDS Medicines
Immunotech Laboratories, Inc.
120 W Pomona ave
Monrovia CA 91016
RECENT GOODIE GAINS : CYBK 39% RITE 38%
Goodies Newsletter Sign Up
WANT A QUICKER WAY TO GET OUR ALERTS?
TEXT "Stock" to 99000
Follow Us on Twitter
Follow StockGoodies Blog
Follow Us on Facebook
Follow Us on PennyStockTweets
As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile. Always do your own Due Diligence.
Sources: http://bloomberg.com - http://finance.yahoo.com - http://businessweek.com - http://otcmarkets.com/marketActivity/current-otc-market
(these are only sources and not always up to date)
If you are new to trading penny stocks we strongly advise you to spend some time trading virtual money. They say that “You never really become a real trader until you wipe out your portfolio.” We say take that wipeout while not losing your real money.
Here are a few sites where you can easily set up a virtual account:
First check your broker. Some have them already like TD Ameritrade/Think or Swim